Bispecific EGFR/IGFIR binding molecules

Patent metadata

Field	Value
Publication number	US-10954286-B2
Application number	US-201816206551-A
Country	US
Kind code	B2
Filing date	Nov 30, 2018
Priority date	Nov 24, 2008
Publication date	Mar 23, 2021
Grant date	Mar 23, 2021

Abstract

The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.

First claim

We claim:

1. An antibody-like protein dimer comprising a tenth fibronectin type III domain ( 10 Fn3) that binds insulin-like growth factor 1 receptor (IGF-IR) with a K D of less than 500 nM covalently or non-covalently linked to a 10 Fn3 that binds epidermal growth factor receptor (EGFR) with a K D of less than 500 nM; wherein
the IGF-IR binding 10 Fn3 comprises a BC loop having the amino acid sequence X a SARLKVAX b (SEQ ID NO: 46), a DE loop having the amino acid sequence X c KNVYX d (SEQ ID NO: 48), and an FG loop having the amino acid sequence X e RFRDYQX f (SEQ ID NO: 50);
the EGFR binding 10 Fn3 comprises a BC loop having the amino acid sequence X g DSGRGSYQX h (SEQ ID NO: 40), a DE loop having the amino acid sequence X i GPVHX j (SEQ ID NO: 42), and an FG loop having the amino acid sequence X k DHKPHADGPHTYHEX l (SEQ ID NO: 44); and
X is any amino acid and a, b, c, d, e, f, g, h, i, j, k, and l are integers independently selected from 0 to 5.

2. The antibody-like protein dimer of claim 1 , wherein
the IGF-IR binding 10 Fn3 comprises a BC loop having the amino acid sequence SWSARLKVAR (SEQ ID NO: 45), a DE loop having the amino acid sequence PKNVYT (SEQ ID NO: 47), and an FG loop having the amino acid sequence TRFRDYQP (SEQ ID NO: 49); and the EGFR binding 10 Fn3 comprises a BC loop having the amino acid sequence SWDSGRGSYQ (SEQ ID NO: 39), a DE loop having the amino acid sequence PGPVHT (SEQ ID NO: 41), and an FG loop having the amino acid sequence TDHKPHADGPHTYHESP (SEQ ID NO: 43).

3. The antibody-like protein dimer of claim 2 , comprising an amino acid sequence at least 90% identical to SEQ ID NO: 20.

4. The antibody-like protein dimer of claim 3 , comprising an amino acid sequence at least 95% identical to SEQ ID NO: 20.

5. The antibody-like protein dimer of claim 4 , comprising an amino acid sequence at least 98% identical to SEQ ID NO: 20.

6. The antibody-like protein dimer of claim 5 , comprising the amino acid sequence of SEQ ID NO: 20.

7. The antibody-like protein dimer of claim 2 , further comprising a C-terminal tail comprising the amino acid sequence of SEQ ID NO: 217.

8. The antibody-like protein dimer of claim 2 , further comprising one or more pharmacokinetic (PK) moieties.

9. The antibody-like protein dimer of claim 8 , wherein the PK moiety is a polyoxyalkylene moiety.

10. The antibody-like protein dimer of claim 9 , wherein the polyoxyalkylene moiety is polyethylene glycol.

11. The antibody-like protein dimer of claim 10 , wherein the polyethylene glycol is between 0.1 kDa and 150 kDa.

12. The antibody-like protein dimer of claim 11 , wherein the polyethylene glycol is linked to the antibody-like protein dimer via a Cys amino acid residue.

13. A pharmaceutically acceptable composition comprising the antibody-like protein dimer of claim 2 .

14. The antibody-like protein dimer of claim 1 , wherein the IGF-IR binding 10 Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 3 and the EGFR binding 10 Fn3 has an amino acid sequence at least 90% identical to SEQ ID NO: 5.

15. The antibody-like protein dimer of claim 14 , wherein the IGF-IR binding 10 Fn3 comprises the amino acid sequence of SEQ ID NO: 3 and the EGFR binding 10 Fn3 comprises the amino acid sequence of SEQ ID NO: 5.

16. A pharmaceutically acceptable composition comprising the antibody-like protein dimer of claim 15 .

17. A pharmaceutically acceptable composition comprising the antibody-like protein dimer of claim 14 .

18. The antibody-like protein dimer of claim 1 , wherein the IGF-IR binding 10 Fn3 is covalently linked to the EGFR binding 10 Fn3 via a polypeptide linker or a polyethylene glycol moiety.

19. The antibody-like protein dimer of claim 18 , comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 20, 21, 23, 24, 25, 56, 58, 90, 92, 101, and 103.

20. A pharmaceutically acceptable composition comprising the antibody-like protein dimer of claim 1 .

Assignees

• Bristol Myers Squibb Co

Inventors

• Emanuel Stuart
• Engle Linda
• Camphausen Ray
• Wright Martin C
• Rakestraw Ginger Chao
• Gottardis Marco
• Carboni Joan

Classifications

• A61K38/39

  Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG] · CPC title

• C07K2318/20

  Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K16/2863

  against receptors for growth factors, growth regulators · CPC title

• C07K14/475

  Growth factors; Growth regulators · CPC title